Despite medical advances, the global burden of malaria is rising. New vaccines are a major turning point; however, funding gaps and persistent structural challenges threaten progress.

Malaria is now considered more manageable than ever before. According to the World Health Organization (WHO), treatment and prevention efforts have prevented about 2.3 billion infections and 14 million deaths since 2000. In addition, 47 high-risk countries have reported no malaria transmission for at least 3 years and are now considered malaria-free by the WHO.

However, recent data revealed a concerning reversal. In 2024, health authorities worldwide reported approximately 282 million malaria cases, an increase of 9 million cases from the previous year.

The WHO African Region remains disproportionately affected and continues to account for most malaria cases and deaths worldwide. Analyses published in 2026 also suggested that the transmission of the disease accelerated in some regions, including Namibia and Mozambique.

Several overlapping challenges are driving this trend, including growing resistance to antimalarial drugs and insecticides, along with climatic and geopolitical pressures.

Vaccines Available

Important advances have emerged in this area. For the first time in the history of malaria control, two vaccines are available for widespread use: the RTS,S/AS01 malaria vaccine and the R21/Matrix-M malaria vaccine.

Both vaccines target the circumsporozoite protein of Plasmodium falciparum during the pre-erythrocytic stage before the parasite infects red blood cells. They are designed to prevent the pathogen from establishing itself in the liver after Anopheles mosquito bites.

Studies have shown that the RTS,S/AS01 malaria vaccine provided protective efficacy ranging from about 30% to 50%, depending on age, exposure, and vaccination schedule. Data from routine use in several African countries have confirmed this benefit. Among children who received three doses of the vaccine, introduction of the RTS,S/AS01 malaria vaccine was associated with a 32% reduction in hospitalizations related to severe malaria and a 9% reduction in overall mortality, excluding injuries. Researchers have also documented a favorable safety profile, with no increased risk for serious adverse events.

R21/Matrix-M, a second malaria vaccine recommended by the WHO and now available, is one of the most important advances in recent years. The vaccine showed efficacy rates ranging from 66% to 75% over 12 months, making it significantly more effective than the RTS,S/AS01 malaria vaccine. Despite its strong efficacy, the vaccine does not provide complete protection and cannot replace mosquito nets or repellents.

Both vaccines also require complex vaccination schedules involving multiple primary doses and booster shots, creating major logistical challenges in resource-limited settings.

Next-Generation Strategies

Current malaria vaccines are an intermediate step rather than a definitive solution. One major obstacle involves the complex biology of P falciparum, which progresses through several developmental stages in both humans and mosquitoes while expressing different antigens at each stage. This high degree of variability complicates the development of vaccines that provide broad and durable protection.

Therefore, researchers are shifting their attention toward newer vaccination strategies. These include whole sporozoite vaccines designed to trigger broader immune responses during the early stage of infection, along with blood-stage vaccines such as RH5-based candidates that specifically inhibit parasite replication in the blood. Researchers are also evaluating transmission-blocking vaccines intended to interrupt the spread of the parasite from humans to mosquitoes.

Researchers are currently investigating approaches that extend beyond traditional vaccines. These include long-acting monoclonal antibodies designed to provide temporary protection. Early studies have suggested that these antibodies can provide significant protection against infection under real-world conditions. A single dose of candidate CIS43LS protected the participants from infection for several months.

Vector Control

Progress is also continuing in vector control, particularly in targeting Anopheles mosquitoes. Traditional approaches such as insecticide-treated mosquito nets remain central to prevention strategies but continue to evolve. For example, next-generation nets that combine multiple active agents are increasingly being used and remain effective against insecticide-resistant mosquito populations.

Genetic approaches have yielded promising results. These include gene-drive technologies that interfere with mosquito reproduction and aim to reduce mosquito populations over time. Researchers are also evaluating the release of sterile male mosquitoes and microbiologic interventions designed to alter mosquitoes’ ability to transmit disease.

Funding Concerns

Although scientific progress in malaria treatment continues, funding constraints are becoming a major concern. According to the WHO, global funding for malaria programs reached about $3.9 billion in 2024, well below the estimated annual need of $7.8 billion to $8.3 billion. This funding gap slows down the expansion of prevention programs, reduces access to diagnostic testing, and delays the introduction of new vaccines.

International donors play a key role in malaria control. Global health partnerships, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and GAVI, the Vaccine Alliance, provide substantial financial support and help coordinate large-scale global programs. At the same time, increasing evidence suggests that geopolitical changes and budget cuts in some donor countries, particularly the US, are already disrupting malaria prevention and treatment programs in the affected regions.

In the private sector, the Bill & Melinda Gates Foundation remains one of the leading contributors to malaria control. The foundation has invested for years in malaria research, vaccine development, new drug development, and mosquito control programs. However, private philanthropic funding cannot fully replace reductions in government funding.

Conclusion: Fragile Progress

World Malaria Day 2026 highlights both the progress achieved and the challenges that remain in the global fight against malaria. Effective vaccines are now available, and ongoing scientific and technological advances continue to expand new possibilities in the fight against this disease.

However, current statistics highlight the fragility of this progress. Rising malaria cases, increasing resistance, and substantial funding gaps are straining advances achieved over recent decades, threatening their long-term durability. The debate is no longer centered on whether malaria can theoretically be eradicated. The more pressing question is whether the global community is willing to provide the necessary financial and structural resources to achieve and maintain that goal on a long-term basis.

This story was translated from Medscape’s German edition.